LAG3 and melanoma: Adjuvant trials using exploratory mechanisms (6 trials) involved 4 immunotherapies including an immune checkpoint inhibitor (1 trial; anti-LAG3), and vaccine therapies (3 trials: POL-103A, Melanoma vaccine modified to express HLA A2/4-1BB ligand, dendritic cell), as well as 2 trials using “other” therapies (beta blockers, vitamin D).